ADRIBLASTINA

This brand name is authorized in Brazil, Cyprus, Estonia, Mexico, Nigeria, Poland, South Africa.

Active ingredients

The drug ADRIBLASTINA contains one active pharmaceutical ingredient (API):

1	Doxorubicin UNII 82F2G7BL4E - DOXORUBICIN HYDROCHLORIDE
	Doxorubicin is a cytotoxic anthracycline antibiotic obtained from Streptomyces peucetius var. caesius. The exact mechanism of the antitumour activity of doxorubicin is not known. It is generally believed that inhibition of DNA, RNA and protein synthesis is responsible for the majority of the cytotoxic effects.
	Read more about Doxorubicin

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01DB01	Doxorubicin	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01D Cytotoxic antibiotics and related substances → L01DB Anthracyclines and related substances
Discover more medicines within L01DB01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	522718030075117, 522718030075217
EE	Ravimiamet	1043064, 1069736, 1793280
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	205M89
NG	Registered Drug Product Database	B4-1159, B4-1160
Switch country to Nigeria in order to find specific presentations of ADRIBLASTINA
PL	Rejestru Produktów Leczniczych	100092424
ZA	Health Products Regulatory Authority	33/26/0102, 33/26/0104, F/26/274, F/26/289, U/26/183